+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII

Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII

Vox Sanguinis 36(6): 369-374

Cryoprecipitate prepared by a rapid thawing technique was pooled in batches of 600--720 donor units and washed with ice-cold Tris-citrate-NaCl solution. After dissolving at 37 degrees C, it was adsorbed with Al(OH)3 and kaolin, and cleared by centrifugation. The supernatant, diluted with 5% dextrose was passed repeatedly through a bed of Celite, filtered through a 293 mm X 0.3 micrometer membrane disc and lyophilized. Typical composition was 15 U . ml-1 factor VII, and 40 mg . ml-1 protein with a yield of 300 U/l of starting plasma. The crude factor VIII concentrate was also a suitable material for preparation of high-purity factor VIII by controlled pore glass chromatography.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 041046208

Download citation: RISBibTeXText

PMID: 494575

DOI: 10.1111/j.1423-0410.1979.tb04514.x

Related references

Stability of factor viii during the preparation of an intermediate purity factor viii concentrate. British Journal of Haematology 53(2): 343, 1983

The impact of a very high purity factor viii concentrate on the immune system of human immunodeficiency virus infected hemophiliacs a randomized prospective two year comparison with an intermediate purity concentrate. Blood 78(8): 1919-1922, 1991

Effects of change in treatment to recombinant factor VIII concentrate in haemophiliac boys previously treated with a single intermediate purity factor VIII concentrate. Blood 94(10 Suppl. 1 Part 2): 97b, 1999

Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thrombosis and Haemostasis 67(3): 310-313, 1992

Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate. Thrombosis and Haemostasis 46(3): 597-601, 1981

A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thrombosis and Haemostasis 69(2): 115-118, 1993

Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate. Vox Sanguinis 65(4): 251-257, 1993

The impact of a very high-purity factor VIII concentrate on the immune system of HIV-infected haemophiliacs: a randomized, two-year comparison with a high-purity concentrate. Haemophilia 2(2): 82-87, 1996

Comparison of recovery and half life of a new factor viii high purity concentrate with a factor viii hs hemate p. Ricerca in Clinica e in Laboratorio 16(1): 231, 1986

The factor viii response to high purity porcine factor viii concentrate in acquired von willebrands disease. Thrombosis & Haemostasis 46(1): 336, 1981

Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent. Thrombosis and Haemostasis 64(2): 251-255, 1990

Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity. Vox Sanguinis 23(5): 402-412, 1972

High-purity vs intermediate-purity factor VIII in HIV positive hemophiliacs Conclusions of a prospective 3-year study. IXTH INTERNATIONAL CONFERENCE ON AIDS AND THE IVTH STD WORLD CONGRESS IXth International Conference on AIDS in affiliation with the IVth STD World Congress : 551, 1993

A new pasteurized high purity factor viii concentrate f viii c hs. Kasper, C K (Ed ) Progress in Clinical And Biological Research, Vol 324 Recent Advances in Hemophilia Care; Symposium, Los Angeles, California, Usa, April 13-15, 1989 Xv+341p Alan R Liss, Inc : New York, New York, Usa Illus 323, 1990

Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate. Vox Sanguinis. 67(Suppl. 1): 51-55, 1994